Antiretroviral Therapy News

 
 
  • AIDS Real-World PrEP Use Virtually Eliminates HIV Transmission The effectiveness of pre-exposure prophylaxis (PrEP) is surpassing expectations, and researchers are seeing stronger HIV prevention rates than were first reported in clinical trials.
  • AIDS Latest HIV Cure Data Expose Resilience of Infection Disappointing results from SEARCH 19 and other recent studies are a challenge for researchers, who must balance progress with the fact that most patients are doing well on antiretroviral therapy.
  • Study Shows Durable Benefits of Early HIV Treatment Early HIV treatment can dramatically reduce the odds of passing the virus on to others, and the protection persists for years, according to final results from a major study that looked at the timing of antiretroviral therapy (ART).
  • Anti-HIV Pill Could Cut Infections in Gay, Bi Men by a Third The rate of new HIV infections among gay and bisexual men could drop by up to a third over the next decade if enough eligible men use pre-exposure prophylaxis (PrEP) with Truvada (emtricitabine/tenofovir disoproxil fumarate), researchers estimate.
  • Condomless Sex May Be Low Risk for Some HIV-Discordant Couples No HIV transmission was detected among discordant couples after condomless sex when viral load remained low in the infected partner, according to a prospective study in heterosexual and MSM couples.
  • Updated HIV Guidelines Integrate Treatment, Prevention Updated recommendations from the International Antiviral Society-USA panel on antiretroviral (ARV) drug therapy for HIV infection integrate treatment and prevention for the first time.
  • Antiretroviral Therapy Weekend Off Does Not Impair HIV Control Taking the weekend off from antiretroviral therapy (ART) does not impair HIV control in children, adolescents, and young adults who are stable on efavirenz-based therapy, according to results from the phase 2/3 BREATHER trial.
  • AIDS Titanic Shift in Attitude Anticipated at AIDS 2016 Since the International AIDS Conference was last held in South Africa, politics have caught up to science, and access to treatment and prevention will now be on the agenda.
  • HIV Pre-Exposure Prophylaxis May Not Be Reaching Those Most at Risk Only a small proportion of gay and bisexual men who could have taken a daily pill to reduce their risk of HIV actually did so in 2014, according to a new study.
  • New Combination Therapy May Be Effective Against Chronic HCV Infection The new NS3/4A protease inhibitor GS-9857, in combination with sofosbuvir and velpatasvir (SOF/VEL), produces sustained viral response in most patients with hepatitis C virus (HCV) genotype 1 or 3 infections, according to a phase 2 trial from Gilead Sciences.
  • Botswana Gets Modern HIV Drug in Largest Africa Tender An HIV drug first approved less than three years ago is to be rolled out in Botswana as a core medicine for newly diagnosed patients, following the largest ever tender secured by GlaxoSmithKline's HIV business in Africa.
  • Single-Dose Drug Decreases Bone Loss in Newly Treated HIV A single dose of zoledronic acid given at the start of ART decreases bone loss over the course of 48 weeks in HIV, according to a small, single-center, proof-of-concept study.
  • Same-Day ART Initiation Improves HIV Treatment Uptake Starting antiretroviral therapy (ART) at HIV patients' first clinic visit increases ART uptake and reduces attrition from care, a new randomized controlled trial shows.
  • Raltegravir Noninferior as Second-Line ART in Low-Resource Settings A raltegravir-based regimen is an "appropriate alternative" for second-line antiretroviral therapy in resource-limited settings, a new phase 3 study confirms.
  • S. African State-Owned Drug Firm Seeks Antiretroviral Supplies South Africa wants antiretroviral drug suppliers to allocate some of their products to a new state-owned pharmaceutical firm, Ketlaphela, a government official said on Friday, part of plans to tackle the country's AIDS problem.
  • Risk for HIV Infection in US Dips, but Racial Gap Still Wide For black males, the risk is one in 20; for white males, it is one in 132. And even with early treatment, life expectancy is nearly a decade less for those who have the virus.
  • Monthly Vaginal Ring Moderately Reduces HIV Risk A vaginal ring inserted monthly helps prevent HIV transmission, two phase 3 sister studies of African women have shown.
  • HIV: Tenofovir Resistance Higher Than Expected A study has found that resistance to tenofovir, often used in first-line treatment in adults with HIV-1, is higher than expected, especially in sub-Saharan Africa.
  • Anti-HCV Drugs Interact With HIV-1 Protease Inhibitors The three-drug direct-acting antiviral (DAA) regimen used to treat hepatitis C virus (HCV) infection is not recommended with evening administration of two HIV-1 protease inhibitor regimens, according to the results of five pharmacokinetic studies in healthy volunteers.
  • Intensive Therapy May Slash Number of New HIV MSM Infections Annual testing and immediate ART for those testing positive and preexposure prophylaxis for half of those who test negative could drastically reduce new cases, according to a new modeling study.
  • GSK to Buy HIV Drugs From BMS for Initial $350 Million Pharmaceutical group GlaxoSmithKline said its majority-owned HIV business would buy drugs at different stages of development from U.S. rival Bristol-Myers Squibb for an initial $350 million.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.